CHRS · Coherus Oncology, Inc.

$1.42 +0.02 (+1.43%) At close · Jul 20

Market Cap

$226.75M

154.25M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Dennis Lanfear	Chairman	$750,737	$195,673	—	$3,547,170	$863,927	$4,200	$5,361,707
Darlene P. Horton	former Chief Medical and Regulatory Affairs Officer	$304,111	$75,000	—	$2,765,938	—	$484,740	$3,629,789
Vincent Anicetti	COO	$469,370	$64,063	—	$993,208	$282,850	$1,350	$1,810,841
Vladimir Vexler	Chief Scientific Officer	$447,525	$58,282	—	$993,208	$257,326	$888	$1,757,229

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Vincent Anicetti	COO	$418,744	$7,509	—	$1,189,683	$202,744	—	$1,818,680
Vladimir Vexler	Chief Scientific Officer	$393,083	$6,874	—	$769,578	$185,628	—	$1,355,163

Key facts CIK 1512762 CUSIP 19249H103 13F (30d) 11 filings 11 filers Visit website Investor relations